7 VC firms investing in marketing & adtech and biotech & life sciences at the Series A stage.
F4 Fund tracks 7 VC firms that actively invest in marketing & adtech + biotech & life sciences at the Series A stage, with check sizes ranging from $100K – $15M (median: $2.6M – $2.6M). As of June 2026, and 100% lead or co-lead rounds. Rankings are based on F4's proprietary analysis of 1,356+ researched VC firms, scored by data completeness, portfolio depth, investment recency, and stage alignment.
| # | Firm | Check Size | Portfolio | Leads? | Activity | Decision | Intro |
|---|---|---|---|---|---|---|---|
| 1 | ▶ Flagship Pioneering Create first-in-category bioplatform companies through scientific innovation and systematic entrepreneurship. Combine institutional scale with pioneer creativity to build breakthrough life sciences companies. Cambridge | $500K – $15M | 22 | Leads | Active | ~1 mo | Req'd |
| 2 | ▶ How Women Invest Women founders represent an overlooked asset class that delivers superior returns. Women-founded companies earn 26% more for investors, yet receive only 2% of venture funding. We invest exclusively in women-founded companies, providing capital, network access, and operational support to drive transformative change. San Francisco | $250K – $5M | 31 | Leads | Active | ~1 mo | Req'd |
| 3 | ▶ Icehouse Ventures Back exceptional Kiwi founders building globally transformative companies, from day one to IPO. New Zealand founders represent a significantly undervalued asset class, and Icehouse provides capital plus an ecosystem of 3,000+ investors and deep operational support. Auckland | $100K – $10M | 41 | Leads | Active | ~2 mo | Open |
| 4 | ▶ Sierra Ventures Sierra believes enterprise software is being fundamentally transformed by cloud computing and AI. They invest in technical founders building the next generation of enterprise solutions that deliver superior ROI through better efficiency, automation, and capability. The firm particularly focuses on infrastructure, security, healthcare innovation, and emerging deep tech. San Mateo, California | $500K – $15M | 28 | Both | Active | ~2 wks | Req'd |
| 5 | ▶ IA Ventures Data is the defensible moat in technology. We invest in companies that build proprietary data assets, analytics capabilities, or machine learning advantages to dominate their categories. Founded on 'information arbitrage' thesis - applying hedge fund quantitative discipline to early-stage venture. New York | $250K – $750K | 16 | Leads | Active | ~2 wks | Open |
| 6 | ▶ ZhenFund Believe in innovation, risk-taking, and young talent. Best entrepreneurs are rare and precious. Provide quick capital, friendly terms, genuine commitment. Help but don't complicate. Monthly founder support. Beijing | $250K – $3M | 25 | Leads | Active | ~2 wks | Open |
| 7 | ▶ Stout Street Capital Great startups can be built anywhere. We believe in founder-centric investing with operational support from a team of successful founders. We serve undernetworked geographic regions. Denver | $100K – $500K | 26 | Both | Active | ~2 wks | Open |
Investors on this page also frequently invest in these sectors
What other stages do these firms also invest in?
What other sectors do these firms also invest in?
F4 Fund tracks 7 VC firms that actively invest in marketing & adtech + biotech & life sciences at the Series A stage. These firms are ranked using a composite score that weighs data completeness (30%), portfolio depth (30%), investment recency (25%), and stage alignment (15%).
Based on F4's analysis, the median check size for series a marketing & adtech + biotech & life sciences investors is $2.6M – $2.6M, with a full range from $100K – $15M. The distribution breaks down as: 1 firms in the <$500K range, 1 firms in the $500K-$1M range, 1 firms in the $1M-$2M range, 1 firms in the $2M-$5M range, 3 firms in the $5M-$10M range.
Among the 7 firms tracked, 100% lead or co-lead rounds. Founders seeking a lead investor should filter for firms marked "Leads" or "Both" in the rankings table above. Lead investors typically set deal terms and anchor the round.
The best series a marketing & adtech + biotech & life sciences investors combine domain expertise with an active portfolio in the space. Among these firms, 43% prefer warm introductions, and the average firm has 27 portfolio companies. Look for firms whose check size matches your raise, whose stage preference aligns with yours, and who have a track record of supporting companies in your sector through multiple growth phases.
Firm profiles are continuously updated through F4's research pipeline, which combines LLM-powered web research, portfolio analysis, and transcript extraction. The ranking data refreshes every 12 hours. Editorial analysis is reviewed weekly. Individual firm profiles are re-researched on a 30-day cycle or when new information surfaces.